TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景

TST008

MASP2-based Tri-functional (FIC)
Target:
MASP2-based Tri-functional (FIC)
Indication:
SLE
Project Status:
Preclinical

TST008 is a first-in-class tri-functional antibody combining a MASP2 antibody fused with a transmembrane activator and CAML interactor (TACI) protein, which simultaneously targets both innate and adaptive immune pathways for a potentially better efficacy for the treatment of SLE.

TOP